The Effect of Bone Wax on Controlling Blood Loss during Total Hip Replacement Surgery

Not Applicable

• Conditions: Primary hip degenerative joint disease.; Unilateral primary osteoarthritis, unspecified hip; M16.10

• Registration Number: IRCT20200305046700N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Patients with hip degenerative joint disease (ICD-10-CM ; M16) with no age and sex limits, and not considering the severity of the disease, who are candidates for elective primary total hip arthroplasty based on the clinical and radiographic workup
The patients should complete and sign the informed consent formula.
The anesthesia method should be spinal anesthesia.

Exclusion Criteria

Any bleeding disorder (ICD-10-CM; D65-D69) including platelet disorders like von Willebrand disease, and coagulation disorders like hemophilia
History of venous thromboembolic accidents like deep vein thrombosis (DVT), pulmonary thromboembolism (PTE), cerebrovascular accidents (CVA), and myocardial infarction (MI)
High-risk medical comorbidities like chronic kidney disease (GFR< 60 mL/min), liver, and heart failure (NYHA classes III , IV)
Inflammatory arthritis of hip joint (ICD-10-CM; M05-M14) like rheumatoid arthritis
Total hip arthroplasty due to acute proximal femoral fracture
Total hip arthroplasty due to developmental dysplasia of hip (DDH) type II and more
Revision total hip arthroplasty
The use of antithrombotic drugs (ATC code; B01) including vitamin K antagonists (B01AA) like warfarin, platelet aggregation inhibitors (B01AA) like clopidogrel, heparin group (B01AB), Factor X inhibitors (B01AF) like rivaroxaban, direct thrombin inhibitors (B01AE) like dabigatran
Impaired coagulation laboratory profile including INR>1.1, aPTT> 1.4, PT> 13.5, or thrombocytopenia < 150,000 per microliter
Any anesthesia method other than spinal anesthesia
Patient cannot or do not want to continue participating in the study or follow-up for any reason

Study & Design

• Study Type: interventional
• Study Design: Not specified